A Light Activated Adhesive to Simplify Surgical Procedures
•
2 likes•1,003 views
This document discusses Gecko Biomedical's development of a light-activated surgical adhesive. Current adhesives have limitations around toxicity, mechanical compatibility, and ability to work in wet environments. Gecko has exclusively licensed 6 patents from MIT and filed 3 new patents for a bioinspired adhesive. It aims to simplify surgery by reducing the need for sutures and enabling minimally invasive procedures. Animal studies show potential for sealing blood vessels and patching heart defects. The company has a strong team and intellectual property position, and seeks to transform surgery from open to minimally invasive approaches.
Report
Share
Report
Share
Download to read offline
Recommended
Worm Glue Can Seal Tissues | August 18, 2014 Issue - Vol. 92 Issue 33 | Chemi...
Russell Stewart and his colleagues are developing a polymer adhesive inspired by the glue produced by sandcastle worms to build their shelters. The adhesive aims to seal ruptures in the amniotic membranes that often occur during fetal surgery and fail to heal, increasing risk of preterm birth. The researchers synthesize oppositely charged polymers that combine to form a complex coacervate adhesive, which is applied and crosslinked on tissues. Initial tests suggest it may effectively seal blood vessels and membranes without cytotoxic effects. If successful, the worm-inspired glue could improve safety of in utero procedures and have other medical and industrial uses.
Ophthalmology Innovation Showcase 2 - Mynosys Cellular Devices
ZeptoTM is a device that uses the Purkinje image to anchor cataract surgery on the visual axis. It completed a US clinical trial in 80 days and was submitted to the FDA for 510(k) clearance in March 2017. The device has launched in India, Germany, and is planned for the US summer 2017. Development is also underway for an automated ZeptoTM for posterior capsulotomy. ZeptoTM aims to increase practice efficiency, allow for difficult cases to be performed easily and safely, and has the potential to redefine cataract surgery.
Mynosys
The document describes a new device called ZEPTO for performing cataract surgery capsulotomies. It uses precision-pulse technology to create an accurate, reproducible capsulotomy that is quick, safe, and affordable. The device applies suction and uses low-energy pulses to precisely cleave the lens capsule. Testing showed it created capsulotomies in rabbit and cadaver eyes without causing temperature increases in surrounding tissues. It was also shown to be safer for the zonules and create stronger capsule edges compared to the conventional capsulorhexis technique. The ZEPTO device aims to automate capsulotomies, reduce procedure time, improve centration, and lower costs.
D2.4.2 peis web_cast version 2
The document proposes a Personal Environmental Information System (PEIS) prototype that would leverage the future internet to provide individuals personalized environmental data and risk assessments. The PEIS would collect data from sensors, monitors, and user inputs to analyze factors like air quality, weather conditions, and activities to determine an individual's environmental exposure risks and offer recommendations to reduce harm. It aims to empower users with information to make more environmentally conscious decisions.
Tissue sealant essentials
There are several types of hemostats and tissue sealants that can be used in surgery to minimize blood loss, improve visualization, and reduce operative time and transfusion needs. Hemostats work by mechanically stopping bleeding or augmenting coagulation, while sealants bind and close tissue defects. Common products include fibrin glues, thrombin-based compounds, collagen and gelatin-based hemostats, and synthetic adhesives. Surgeons consider factors like cost, application method, speed of hemostasis, and biocompatibility when choosing the appropriate product.
Use Of Tissue Sealants And Hemostatic Agents
This document summarizes various hemostatic agents and tissue sealants used in surgery. It discusses collagen products, oxidized regenerated cellulose, gelatin sponges, flowable gelatins, thrombin, and fibrin sealants. For each product, it describes the composition, mechanisms of action, advantages, disadvantages, and differences between brands. The document provides an overview of the history and development of hemostatic agents over the past century.
Management of Surgical Hemostasis: An Independent Study Guide
Management of Surgical Hemostasis: An Independent Study GuideAssociation of periOperative Registered Nurses (AORN)
Effective management of hemostasis during surgery is critical for the patient. Using the nursing process and evidence-based practices, this independent study program will assist the perioperative RN identify risks, benefits, indications, contraindications, and adverse effects for the various methods available for control of bleeding during surgery. The goal of this learning activity is to educate perioperative RNs about the methods for effective management of hemostasis during surgery to promote positive outcomes for the surgical patient.
Objectives
After completion of this continuing nursing education activity, the participant will be able to:
1. Identify the clinical implications of surgical bleeding.
2. Differentiate between mechanical, energy-based, and chemical methods of surgical hemostasis.
3. Compare the various categories of topical hemostatic products.
4. Identify key factors to consider in the selection of hemostatic products.
5. Describe perioperative nursing care for patients undergoing surgical hemostasis.
2.4 Contact Hours are available through AORN. Learn more at http://bit.ly/HemostasisStudyGuide. This education program was funded through the AORN Foundation by a grant from Ethicon Biosurgery.Implants & prosthetics / /certified fixed orthodontic courses by Indian denta...
Implants & prosthetics / /certified fixed orthodontic courses by Indian denta...Indian dental academy
The Indian Dental Academy is the Leader in continuing dental education , training dentists in all aspects of dentistry and offering a wide range of dental certified courses in different formats.
Indian dental academy provides dental crown & Bridge,rotary endodontics,fixed orthodontics,
Dental implants courses.for details pls visit www.indiandentalacademy.com ,or call
00919248678078Recommended
Worm Glue Can Seal Tissues | August 18, 2014 Issue - Vol. 92 Issue 33 | Chemi...
Russell Stewart and his colleagues are developing a polymer adhesive inspired by the glue produced by sandcastle worms to build their shelters. The adhesive aims to seal ruptures in the amniotic membranes that often occur during fetal surgery and fail to heal, increasing risk of preterm birth. The researchers synthesize oppositely charged polymers that combine to form a complex coacervate adhesive, which is applied and crosslinked on tissues. Initial tests suggest it may effectively seal blood vessels and membranes without cytotoxic effects. If successful, the worm-inspired glue could improve safety of in utero procedures and have other medical and industrial uses.
Ophthalmology Innovation Showcase 2 - Mynosys Cellular Devices
ZeptoTM is a device that uses the Purkinje image to anchor cataract surgery on the visual axis. It completed a US clinical trial in 80 days and was submitted to the FDA for 510(k) clearance in March 2017. The device has launched in India, Germany, and is planned for the US summer 2017. Development is also underway for an automated ZeptoTM for posterior capsulotomy. ZeptoTM aims to increase practice efficiency, allow for difficult cases to be performed easily and safely, and has the potential to redefine cataract surgery.
Mynosys
The document describes a new device called ZEPTO for performing cataract surgery capsulotomies. It uses precision-pulse technology to create an accurate, reproducible capsulotomy that is quick, safe, and affordable. The device applies suction and uses low-energy pulses to precisely cleave the lens capsule. Testing showed it created capsulotomies in rabbit and cadaver eyes without causing temperature increases in surrounding tissues. It was also shown to be safer for the zonules and create stronger capsule edges compared to the conventional capsulorhexis technique. The ZEPTO device aims to automate capsulotomies, reduce procedure time, improve centration, and lower costs.
D2.4.2 peis web_cast version 2
The document proposes a Personal Environmental Information System (PEIS) prototype that would leverage the future internet to provide individuals personalized environmental data and risk assessments. The PEIS would collect data from sensors, monitors, and user inputs to analyze factors like air quality, weather conditions, and activities to determine an individual's environmental exposure risks and offer recommendations to reduce harm. It aims to empower users with information to make more environmentally conscious decisions.
Tissue sealant essentials
There are several types of hemostats and tissue sealants that can be used in surgery to minimize blood loss, improve visualization, and reduce operative time and transfusion needs. Hemostats work by mechanically stopping bleeding or augmenting coagulation, while sealants bind and close tissue defects. Common products include fibrin glues, thrombin-based compounds, collagen and gelatin-based hemostats, and synthetic adhesives. Surgeons consider factors like cost, application method, speed of hemostasis, and biocompatibility when choosing the appropriate product.
Use Of Tissue Sealants And Hemostatic Agents
This document summarizes various hemostatic agents and tissue sealants used in surgery. It discusses collagen products, oxidized regenerated cellulose, gelatin sponges, flowable gelatins, thrombin, and fibrin sealants. For each product, it describes the composition, mechanisms of action, advantages, disadvantages, and differences between brands. The document provides an overview of the history and development of hemostatic agents over the past century.
Management of Surgical Hemostasis: An Independent Study Guide
Management of Surgical Hemostasis: An Independent Study GuideAssociation of periOperative Registered Nurses (AORN)
Effective management of hemostasis during surgery is critical for the patient. Using the nursing process and evidence-based practices, this independent study program will assist the perioperative RN identify risks, benefits, indications, contraindications, and adverse effects for the various methods available for control of bleeding during surgery. The goal of this learning activity is to educate perioperative RNs about the methods for effective management of hemostasis during surgery to promote positive outcomes for the surgical patient.
Objectives
After completion of this continuing nursing education activity, the participant will be able to:
1. Identify the clinical implications of surgical bleeding.
2. Differentiate between mechanical, energy-based, and chemical methods of surgical hemostasis.
3. Compare the various categories of topical hemostatic products.
4. Identify key factors to consider in the selection of hemostatic products.
5. Describe perioperative nursing care for patients undergoing surgical hemostasis.
2.4 Contact Hours are available through AORN. Learn more at http://bit.ly/HemostasisStudyGuide. This education program was funded through the AORN Foundation by a grant from Ethicon Biosurgery.Implants & prosthetics / /certified fixed orthodontic courses by Indian denta...
Implants & prosthetics / /certified fixed orthodontic courses by Indian denta...Indian dental academy
The Indian Dental Academy is the Leader in continuing dental education , training dentists in all aspects of dentistry and offering a wide range of dental certified courses in different formats.
Indian dental academy provides dental crown & Bridge,rotary endodontics,fixed orthodontics,
Dental implants courses.for details pls visit www.indiandentalacademy.com ,or call
00919248678078Nviv - final 8-8-11 pdf one
InVivo Therapeutics is developing novel treatments for spinal cord injuries. Their lead product is a biodegradable polymer scaffold implant designed to be placed in the spinal cord after injury. Animal trials showed functional recovery in treated animals. The company plans to begin human trials in early 2012. InVivo also has additional products in development and exclusive rights to develop biomaterial devices for spinal cord and other injuries. Management has extensive experience in biotechnology, medical devices, and spinal cord injury research. The addressable market for spinal cord injury treatments is large, with the potential for InVivo's scaffold product to generate over $150 million in annual sales within 3-4 years.
Ophthalmology Innovation Showcase 1 - InnFocus (A Santen Company)
The InnFocus MicroShunt is designed to be the first FDA-approved standalone procedure to treat mild, moderate, and severe open-angle glaucoma by lowering intraocular pressure under 15 mmHg without eye drops in most patients. It uses a unique SIBS material that has been proven biocompatible and shown not to degrade or provoke scarring over 15 years of use in over 1 million patients. Clinical trials have demonstrated the MicroShunt's ability to successfully lower IOP long-term while maintaining an acceptable safety profile. The MicroShunt offers surgeons a potential replacement for trabeculectomy and tubes with advantages in both safety and operating time.
Orthopedic implant brochure
This novel orthopedic implant has been developed to simultaneously promote bone integration and prevent infection. Key features include sustained antibiotic release up to 180 hours, enhanced fracture toughness of 29%, and improved mechanical properties. It has been validated on a lab scale, showing favorable biocompatibility, antimicrobial activity, and increased fracture toughness. The implant is a metal implant coated with hydroxyapatite loaded with antibiotics via a novel method. It is intended to treat bone injuries and diseases by replacing damaged bone while reducing early implant failure due to infection.
THE PRACTICE OF EMERGENCY MEDICINEORIGINAL RESEARCH196 Ann.docx
THE PRACTICE OF EMERGENCY MEDICINE/ORIGINAL RESEARCH
196 Ann
Skin Glue Reduces the Failure Rate of Emergency
Department–Inserted Peripheral Intravenous Catheters:
A Randomized Controlled Trial
Simon Bugden, MBChB, FACEM*; Karla Shean, RN; Mark Scott, MBBS, FACEM; Gabor Mihala, MEng(Mech), GradCert(Biostatistics);
Sean Clark, MBBS, FACEM; Christopher Johnstone, MBChB, FACEM; John F. Fraser, MD, PhD; Claire M. Rickard, PhD, RN
*Corresponding Author. E-mail: [email protected]
Study objective: Peripheral intravenous catheters are the most common invasive device in health care yet have very
high failure rates. We investigate whether the failure rate could be reduced by the addition of skin glue to standard
peripheral intravenous catheter care.
Methods: We conducted a single-site, 2-arm, nonblinded, randomized, controlled trial of 380 peripheral intravenous
catheters inserted into 360 adult patients. The standard care group received standard securement. The skin glue group
received standard securement plus cyanoacrylate skin glue applied to the skin insertion site. The primary outcome was
peripheral intravenous catheter failure at 48 hours, regardless of cause. Secondary outcomes were the individual
modes of peripheral intravenous catheter failure: infection, phlebitis, occlusion, or dislodgement.
Results: Peripheral intravenous catheter failure was 10% lower (95% confidence interval –18% to –2%; P¼.02) with
skin glue (17%) than standard care (27%), and dislodgement was 7% lower (95% confidence interval –13% to 0%;
P¼.04). Phlebitis and occlusion were less with skin glue but were not statistically significant. There were no infections.
Conclusion: This study supports the use of skin glue in addition to standard care to reduce peripheral intravenous catheter
failure rates for adult emergency department patients admitted to the hospital. [Ann Emerg Med. 2016;68:196-201.]
Please see page 197 for the Editor’s Capsule Summary of this article.
A feedback survey is available with each research article published on the Web at www.annemergmed.com.
A podcast for this article is available at www.annemergmed.com.
0196-0644/$-see front matter
Copyright © 2015 by the American College of Emergency Physicians.
http://dx.doi.org/10.1016/j.annemergmed.2015.11.026
INTRODUCTION
Background
Peripheral intravenous catheters are the most commonly
used medical invasive device in hospitals today, inserted in
up to 80% of all hospitalized patients during their stay and
frequently initiated in the emergency department (ED).1,2
Premature device failure is reported to occur in 33% to
69% of devices because of infection, phlebitis, occlusion,
or dislodgement.3 A major contributing factor to device
failure is inadequate fixation of the peripheral intravenous
catheter to the patient’s skin, causing not just dislodgement
but also micromotion, leading to vein irritation (phlebitis
or occlusion) and entry of skin bacteria into the entry
site (infection).3 Peripheral intrave ...
NEWS RELEASE/FEATURE
A KU researcher is developing a synthetic patch to replace rib cartilage used in tracheal surgery for infants with tracheal stenosis. The synthetic patch is made of a biodegradable material and is easier to mold than rib cartilage, making the surgery safer and simpler. The researcher's tracheal patch was selected to present at a symposium to help advance new university technologies and find partnerships to bring the patch to market helping thousands of infants each year.
SilkBiomaterials - Investors Deck
A tissue engineering company is developing SilkByPass, the first vascular graft made of fibroin silk, to help patients regenerate new blood vessels. SilkByPass uses a combination of nano-fibrous electrospun silk fibroin and micro-fibrous silk fabrics to stimulate fast, natural human tissue regeneration without cells, drugs, or growth factors. Preclinical studies show SilkByPass integrates with the body and regenerates functional vascular tissue within 7 days with no immune rejection. The company aims to address the $4 billion market for tissue engineered vascular grafts.
U-Cann Article to send
This document discusses the issues with current intravenous cannulation procedures and introduces a new cannulation device called the U-Cannula. It notes that current cannulation techniques often require multiple puncture attempts, which increases trauma, risk of infection, and healthcare costs. The U-Cannula aims to address this by using an introducer strap to smoothly guide the cannula into place in one attempt. Clinical studies found the U-Cannula successful in 94% of first attempts compared to average attempts of 2.48 for standard cannulas. While the concept has support from doctors, major manufacturers have been reluctant due to concerns it could reduce skills or increase costs. The document argues the U-Cannula could help reduce infection
Opportunities and challenges in Laryngeal Microsurgery- A graduate seminar pr...
This document summarizes a presentation on opportunities and challenges in laryngeal microsurgery. It introduces vocal fold pathology and interventions like excision of lesions. It discusses the setup for microlaryngeal surgery on pigs and patients. Experimental task analysis found that a single microclip provided superior holding strength to resist low strains compared to a suture. Microclips were also faster to deploy than sutures. Further investigation of microclip mechanical properties at low strains over time was recommended. The document suggests microclips have potential as alternatives for wound closure in situations with minimal displacement and could be customized and quickly deployed, representing disruptive innovation compared to sutures.
Team A Robotic Surgery Presentation.pptx
Robotic surgery was developed to enable minimally invasive surgery using telepresence and tactile sensor technologies. The Da Vinci surgical system, first used in 2000, allows surgeons to control robotic arms and cameras from a console. While robotic surgery enables more precise movements and 3D visualization, concerns include the high costs of robotic systems, lack of evidence that it improves outcomes compared to laparoscopic surgery, and safety issues such as injuries caused by robotic arms. The future of robotic surgery will depend on addressing these challenges and improving training as the technology continues to advance.
Medvantage Tech Overview
Medvantage International has acquired rights to a new vascular coupling device called CUVASLAR that represents an alternative to manual suturing for connecting arteries and veins. The device is expected to reduce surgical time, minimize errors from suturing, and improve patient outcomes. Medvantage plans to submit the device for FDA approval over the next year and market it to the 340,000 microsurgery procedures performed annually in the US.
Capstone final poster group 8
This document describes the development of a device capable of applying a polymer blend via blow spinning laparoscopically. The current method requires open surgery. The researchers designed a 5mm diameter, 20-30cm long device that can withstand pressures of 15mmHg and successfully deliver PLGA/PEG polymer nanofibers during testing. Future work includes animal studies and a trigger mechanism to control polymer release. The global market for laparoscopic devices is growing, indicating potential for this technology.
Sterilization in Orthodontics
This document summarizes a study that compared four methods for sterilizing orthodontic pliers: wrapped cassettes in an M11 ultraclave sterilizer, V-shaped pouches in an M11 ultraclave, wrapped cassettes in a Statim 5000 sterilizer, and V-shaped pouches in a Statim 5000. The study found that the most efficient method was using V-shaped pouches in the larger M11 ultraclave sterilizer, while the least efficient was using wrapped cassettes in the smaller Statim 5000 sterilizer. Following CDC guidelines and using pouches designed for hinged instruments like pliers allows for better sterilization than cassettes. While all methods
HealthPACT_WP102_update
1. The document provides an update on evidence for the use of the InteguSeal® microbial sealant to reduce surgical site infections following cardiac surgery.
2. Two studies were included in the update - a randomized controlled trial and a pseudo-randomized controlled trial comparing the sealant to standard cleaning and draping.
3. The sealant forms a continuous, breathable barrier on the skin to immobilize bacteria and prevent migration into incision sites, with the goal of reducing surgical site infections.
Can Smart Bandages be the Next Negative-pressure Wound Therapy
Smart bandages are a new concept in wound care that can sense the state of a wound and address challenges in treating hard-to-heal wounds. Researchers are developing smart bandages with sensors that can detect bacteria, pH levels, temperature and release antibiotics as needed. These bandages have potential to speed healing, reduce costs and complications compared to traditional bandages. Several universities and companies are working on prototypes that monitor wounds and vital signs and wirelessly communicate with doctors. While smart bandages show promise in chronic wound management, more clinical testing is still needed before commercialization.
Article IVD March 2006
The key technological advances in assay development in recent years have been the use of magnetic microspheres and polymer beads as the solid phase in automated immunoassays. This has enabled automation, faster reactions, increased sensitivity, and shorter assay times. Magnetic beads and polymer beads allow assays to work in three dimensions, dramatically increasing surface area and sensitivity compared to traditional ELISAs or coated tubes. IVD manufacturers must consider factors like accuracy, reproducibility, stability, and ease of adaptation when developing assays for instrument systems. Forming collaborations with academic researchers is important for assay development to help discover new biomarkers and opportunities to add new tests.
Future Diagnostics, In Vitro Diagnostiek "Bloedserieus"
Future Diagnostics strives to become a leading developer of innovative diagnostic tests. It aims to be the preferred partner of top IVD companies for outsourced test development. The company was founded in 1997 and now has 60 employees working on 34 projects. It has two facilities and is certified under ISO and FDA quality standards. Future Diagnostics has experience developing assays for various analytes on automated platforms and is interested in point-of-care tests and new testing technologies.
WTF@OIS: WHAT’S THE FUTURE @OIS?
Presentation from OIS@ASCRS 2016
Co-Moderators:
Gilbert H. Kliman, MD, Managing Director – InterWest Partners
Stephen Slade, MD
Company Presentations
Equinox | John Berdahl, MD, Founder & CEO
Presbyopia Therapies | Jim McCollum, Co-Founder
Stroma Medical | Doug Daniels, CEO
Eyenovia | Curt LaBelle, MD, Director
Wicab | Robert Beckman, President & COO
NovaTissue Presentation
This document summarizes a technology for tissue regeneration using a biopolymer or biopolymer/ceramic composite to assemble 3D porous structures incorporating a pre-vascular network. This technology aims to help the body heal itself faster than normal by providing a scaffold that nourishes regenerating cells. It has applications in orthopedics, veterinary dentistry, and plastic surgery. Currently, bone grafting requires over 2 million surgical procedures annually but options are limited by donor site complications, limited availability, long regeneration times, and high costs. The presented technology offers benefits over current solutions like being vascularized, shapable, and always available without rejection risks. Its marketing strategy involves workshops, trade shows, and conferences to introduce Ortho Nova
Open Source Pharma: OSDD: An innovative model for distributed co-creation
This document summarizes Prof. Samir K. Brahmachari's presentation on the Open Source Drug Discovery (OSDD) initiative. The key points are:
1) OSDD is an open innovation model for collaborative drug discovery pioneered by CSIR India, with over 8,000 registered participants from 130 countries working to develop affordable treatments for tuberculosis, malaria, and leishmaniasis.
2) OSDD functions like a virtual distributed laboratory, leveraging the expertise of researchers across institutions worldwide. It has identified several potential drug targets for tuberculosis and progressed some candidate molecules through screening and testing.
3) Since its launch in 2008, OSDD has grown significantly in its community,
Anteo Diagnostics Microcap Presentation October 2013
Anteo Diagnostics, Biotech, Microcap, Investing, ASX, Stockmarket, Geoff Cumming, Alere, Philips Healthcare, BBI Solutions
Cell Therapy Expansion and Challenges in Autoimmune Disease
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
More Related Content
Similar to A Light Activated Adhesive to Simplify Surgical Procedures
Nviv - final 8-8-11 pdf one
InVivo Therapeutics is developing novel treatments for spinal cord injuries. Their lead product is a biodegradable polymer scaffold implant designed to be placed in the spinal cord after injury. Animal trials showed functional recovery in treated animals. The company plans to begin human trials in early 2012. InVivo also has additional products in development and exclusive rights to develop biomaterial devices for spinal cord and other injuries. Management has extensive experience in biotechnology, medical devices, and spinal cord injury research. The addressable market for spinal cord injury treatments is large, with the potential for InVivo's scaffold product to generate over $150 million in annual sales within 3-4 years.
Ophthalmology Innovation Showcase 1 - InnFocus (A Santen Company)
The InnFocus MicroShunt is designed to be the first FDA-approved standalone procedure to treat mild, moderate, and severe open-angle glaucoma by lowering intraocular pressure under 15 mmHg without eye drops in most patients. It uses a unique SIBS material that has been proven biocompatible and shown not to degrade or provoke scarring over 15 years of use in over 1 million patients. Clinical trials have demonstrated the MicroShunt's ability to successfully lower IOP long-term while maintaining an acceptable safety profile. The MicroShunt offers surgeons a potential replacement for trabeculectomy and tubes with advantages in both safety and operating time.
Orthopedic implant brochure
This novel orthopedic implant has been developed to simultaneously promote bone integration and prevent infection. Key features include sustained antibiotic release up to 180 hours, enhanced fracture toughness of 29%, and improved mechanical properties. It has been validated on a lab scale, showing favorable biocompatibility, antimicrobial activity, and increased fracture toughness. The implant is a metal implant coated with hydroxyapatite loaded with antibiotics via a novel method. It is intended to treat bone injuries and diseases by replacing damaged bone while reducing early implant failure due to infection.
THE PRACTICE OF EMERGENCY MEDICINEORIGINAL RESEARCH196 Ann.docx
THE PRACTICE OF EMERGENCY MEDICINE/ORIGINAL RESEARCH
196 Ann
Skin Glue Reduces the Failure Rate of Emergency
Department–Inserted Peripheral Intravenous Catheters:
A Randomized Controlled Trial
Simon Bugden, MBChB, FACEM*; Karla Shean, RN; Mark Scott, MBBS, FACEM; Gabor Mihala, MEng(Mech), GradCert(Biostatistics);
Sean Clark, MBBS, FACEM; Christopher Johnstone, MBChB, FACEM; John F. Fraser, MD, PhD; Claire M. Rickard, PhD, RN
*Corresponding Author. E-mail: [email protected]
Study objective: Peripheral intravenous catheters are the most common invasive device in health care yet have very
high failure rates. We investigate whether the failure rate could be reduced by the addition of skin glue to standard
peripheral intravenous catheter care.
Methods: We conducted a single-site, 2-arm, nonblinded, randomized, controlled trial of 380 peripheral intravenous
catheters inserted into 360 adult patients. The standard care group received standard securement. The skin glue group
received standard securement plus cyanoacrylate skin glue applied to the skin insertion site. The primary outcome was
peripheral intravenous catheter failure at 48 hours, regardless of cause. Secondary outcomes were the individual
modes of peripheral intravenous catheter failure: infection, phlebitis, occlusion, or dislodgement.
Results: Peripheral intravenous catheter failure was 10% lower (95% confidence interval –18% to –2%; P¼.02) with
skin glue (17%) than standard care (27%), and dislodgement was 7% lower (95% confidence interval –13% to 0%;
P¼.04). Phlebitis and occlusion were less with skin glue but were not statistically significant. There were no infections.
Conclusion: This study supports the use of skin glue in addition to standard care to reduce peripheral intravenous catheter
failure rates for adult emergency department patients admitted to the hospital. [Ann Emerg Med. 2016;68:196-201.]
Please see page 197 for the Editor’s Capsule Summary of this article.
A feedback survey is available with each research article published on the Web at www.annemergmed.com.
A podcast for this article is available at www.annemergmed.com.
0196-0644/$-see front matter
Copyright © 2015 by the American College of Emergency Physicians.
http://dx.doi.org/10.1016/j.annemergmed.2015.11.026
INTRODUCTION
Background
Peripheral intravenous catheters are the most commonly
used medical invasive device in hospitals today, inserted in
up to 80% of all hospitalized patients during their stay and
frequently initiated in the emergency department (ED).1,2
Premature device failure is reported to occur in 33% to
69% of devices because of infection, phlebitis, occlusion,
or dislodgement.3 A major contributing factor to device
failure is inadequate fixation of the peripheral intravenous
catheter to the patient’s skin, causing not just dislodgement
but also micromotion, leading to vein irritation (phlebitis
or occlusion) and entry of skin bacteria into the entry
site (infection).3 Peripheral intrave ...
NEWS RELEASE/FEATURE
A KU researcher is developing a synthetic patch to replace rib cartilage used in tracheal surgery for infants with tracheal stenosis. The synthetic patch is made of a biodegradable material and is easier to mold than rib cartilage, making the surgery safer and simpler. The researcher's tracheal patch was selected to present at a symposium to help advance new university technologies and find partnerships to bring the patch to market helping thousands of infants each year.
SilkBiomaterials - Investors Deck
A tissue engineering company is developing SilkByPass, the first vascular graft made of fibroin silk, to help patients regenerate new blood vessels. SilkByPass uses a combination of nano-fibrous electrospun silk fibroin and micro-fibrous silk fabrics to stimulate fast, natural human tissue regeneration without cells, drugs, or growth factors. Preclinical studies show SilkByPass integrates with the body and regenerates functional vascular tissue within 7 days with no immune rejection. The company aims to address the $4 billion market for tissue engineered vascular grafts.
U-Cann Article to send
This document discusses the issues with current intravenous cannulation procedures and introduces a new cannulation device called the U-Cannula. It notes that current cannulation techniques often require multiple puncture attempts, which increases trauma, risk of infection, and healthcare costs. The U-Cannula aims to address this by using an introducer strap to smoothly guide the cannula into place in one attempt. Clinical studies found the U-Cannula successful in 94% of first attempts compared to average attempts of 2.48 for standard cannulas. While the concept has support from doctors, major manufacturers have been reluctant due to concerns it could reduce skills or increase costs. The document argues the U-Cannula could help reduce infection
Opportunities and challenges in Laryngeal Microsurgery- A graduate seminar pr...
This document summarizes a presentation on opportunities and challenges in laryngeal microsurgery. It introduces vocal fold pathology and interventions like excision of lesions. It discusses the setup for microlaryngeal surgery on pigs and patients. Experimental task analysis found that a single microclip provided superior holding strength to resist low strains compared to a suture. Microclips were also faster to deploy than sutures. Further investigation of microclip mechanical properties at low strains over time was recommended. The document suggests microclips have potential as alternatives for wound closure in situations with minimal displacement and could be customized and quickly deployed, representing disruptive innovation compared to sutures.
Team A Robotic Surgery Presentation.pptx
Robotic surgery was developed to enable minimally invasive surgery using telepresence and tactile sensor technologies. The Da Vinci surgical system, first used in 2000, allows surgeons to control robotic arms and cameras from a console. While robotic surgery enables more precise movements and 3D visualization, concerns include the high costs of robotic systems, lack of evidence that it improves outcomes compared to laparoscopic surgery, and safety issues such as injuries caused by robotic arms. The future of robotic surgery will depend on addressing these challenges and improving training as the technology continues to advance.
Medvantage Tech Overview
Medvantage International has acquired rights to a new vascular coupling device called CUVASLAR that represents an alternative to manual suturing for connecting arteries and veins. The device is expected to reduce surgical time, minimize errors from suturing, and improve patient outcomes. Medvantage plans to submit the device for FDA approval over the next year and market it to the 340,000 microsurgery procedures performed annually in the US.
Capstone final poster group 8
This document describes the development of a device capable of applying a polymer blend via blow spinning laparoscopically. The current method requires open surgery. The researchers designed a 5mm diameter, 20-30cm long device that can withstand pressures of 15mmHg and successfully deliver PLGA/PEG polymer nanofibers during testing. Future work includes animal studies and a trigger mechanism to control polymer release. The global market for laparoscopic devices is growing, indicating potential for this technology.
Sterilization in Orthodontics
This document summarizes a study that compared four methods for sterilizing orthodontic pliers: wrapped cassettes in an M11 ultraclave sterilizer, V-shaped pouches in an M11 ultraclave, wrapped cassettes in a Statim 5000 sterilizer, and V-shaped pouches in a Statim 5000. The study found that the most efficient method was using V-shaped pouches in the larger M11 ultraclave sterilizer, while the least efficient was using wrapped cassettes in the smaller Statim 5000 sterilizer. Following CDC guidelines and using pouches designed for hinged instruments like pliers allows for better sterilization than cassettes. While all methods
HealthPACT_WP102_update
1. The document provides an update on evidence for the use of the InteguSeal® microbial sealant to reduce surgical site infections following cardiac surgery.
2. Two studies were included in the update - a randomized controlled trial and a pseudo-randomized controlled trial comparing the sealant to standard cleaning and draping.
3. The sealant forms a continuous, breathable barrier on the skin to immobilize bacteria and prevent migration into incision sites, with the goal of reducing surgical site infections.
Can Smart Bandages be the Next Negative-pressure Wound Therapy
Smart bandages are a new concept in wound care that can sense the state of a wound and address challenges in treating hard-to-heal wounds. Researchers are developing smart bandages with sensors that can detect bacteria, pH levels, temperature and release antibiotics as needed. These bandages have potential to speed healing, reduce costs and complications compared to traditional bandages. Several universities and companies are working on prototypes that monitor wounds and vital signs and wirelessly communicate with doctors. While smart bandages show promise in chronic wound management, more clinical testing is still needed before commercialization.
Article IVD March 2006
The key technological advances in assay development in recent years have been the use of magnetic microspheres and polymer beads as the solid phase in automated immunoassays. This has enabled automation, faster reactions, increased sensitivity, and shorter assay times. Magnetic beads and polymer beads allow assays to work in three dimensions, dramatically increasing surface area and sensitivity compared to traditional ELISAs or coated tubes. IVD manufacturers must consider factors like accuracy, reproducibility, stability, and ease of adaptation when developing assays for instrument systems. Forming collaborations with academic researchers is important for assay development to help discover new biomarkers and opportunities to add new tests.
Future Diagnostics, In Vitro Diagnostiek "Bloedserieus"
Future Diagnostics strives to become a leading developer of innovative diagnostic tests. It aims to be the preferred partner of top IVD companies for outsourced test development. The company was founded in 1997 and now has 60 employees working on 34 projects. It has two facilities and is certified under ISO and FDA quality standards. Future Diagnostics has experience developing assays for various analytes on automated platforms and is interested in point-of-care tests and new testing technologies.
WTF@OIS: WHAT’S THE FUTURE @OIS?
Presentation from OIS@ASCRS 2016
Co-Moderators:
Gilbert H. Kliman, MD, Managing Director – InterWest Partners
Stephen Slade, MD
Company Presentations
Equinox | John Berdahl, MD, Founder & CEO
Presbyopia Therapies | Jim McCollum, Co-Founder
Stroma Medical | Doug Daniels, CEO
Eyenovia | Curt LaBelle, MD, Director
Wicab | Robert Beckman, President & COO
NovaTissue Presentation
This document summarizes a technology for tissue regeneration using a biopolymer or biopolymer/ceramic composite to assemble 3D porous structures incorporating a pre-vascular network. This technology aims to help the body heal itself faster than normal by providing a scaffold that nourishes regenerating cells. It has applications in orthopedics, veterinary dentistry, and plastic surgery. Currently, bone grafting requires over 2 million surgical procedures annually but options are limited by donor site complications, limited availability, long regeneration times, and high costs. The presented technology offers benefits over current solutions like being vascularized, shapable, and always available without rejection risks. Its marketing strategy involves workshops, trade shows, and conferences to introduce Ortho Nova
Open Source Pharma: OSDD: An innovative model for distributed co-creation
This document summarizes Prof. Samir K. Brahmachari's presentation on the Open Source Drug Discovery (OSDD) initiative. The key points are:
1) OSDD is an open innovation model for collaborative drug discovery pioneered by CSIR India, with over 8,000 registered participants from 130 countries working to develop affordable treatments for tuberculosis, malaria, and leishmaniasis.
2) OSDD functions like a virtual distributed laboratory, leveraging the expertise of researchers across institutions worldwide. It has identified several potential drug targets for tuberculosis and progressed some candidate molecules through screening and testing.
3) Since its launch in 2008, OSDD has grown significantly in its community,
Anteo Diagnostics Microcap Presentation October 2013
Anteo Diagnostics, Biotech, Microcap, Investing, ASX, Stockmarket, Geoff Cumming, Alere, Philips Healthcare, BBI Solutions
Similar to A Light Activated Adhesive to Simplify Surgical Procedures (20)
Ophthalmology Innovation Showcase 1 - InnFocus (A Santen Company)
Ophthalmology Innovation Showcase 1 - InnFocus (A Santen Company)
THE PRACTICE OF EMERGENCY MEDICINEORIGINAL RESEARCH196 Ann.docx
THE PRACTICE OF EMERGENCY MEDICINEORIGINAL RESEARCH196 Ann.docx
Opportunities and challenges in Laryngeal Microsurgery- A graduate seminar pr...
Opportunities and challenges in Laryngeal Microsurgery- A graduate seminar pr...
Can Smart Bandages be the Next Negative-pressure Wound Therapy
Can Smart Bandages be the Next Negative-pressure Wound Therapy
Future Diagnostics, In Vitro Diagnostiek "Bloedserieus"
Future Diagnostics, In Vitro Diagnostiek "Bloedserieus"
Open Source Pharma: OSDD: An innovative model for distributed co-creation
Open Source Pharma: OSDD: An innovative model for distributed co-creation
Anteo Diagnostics Microcap Presentation October 2013
Anteo Diagnostics Microcap Presentation October 2013
Recently uploaded
Cell Therapy Expansion and Challenges in Autoimmune Disease
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
NVBDCP.pptx Nation vector borne disease control program
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.Efficacy of Avartana Sneha in Ayurveda
Avartana Sneha is a unique method of Preparation of Sneha Kalpana in Ayurveda, mainly it is indicated for the Vataja rogas.
Best Ayurvedic medicine for Gas and Indigestion
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
The Best Ayurvedic Antacid Tablets in India
Treat the symptoms of indigestion, heartburn and stomach reflux with the 10 Best Ayurvedic Antacid Tablets in India.
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
It includes regulation of combination products and medical devices. FDA and industry liaisons.
The Electrocardiogram - Physiologic Principles
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Light House Retreats: Plant Medicine Retreat Europe
Our aim is to organise conscious gatherings and retreats for open and inquisitive minds and souls, with and without the assistance of sacred plants.
Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...
Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...chandankumarsmartiso
Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel With 100% Satisfaction
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
A Classical Text Review on Basavarajeeyam
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeProf. Marcus Renato de Carvalho
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Recently uploaded (20)
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...
Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
A Light Activated Adhesive to Simplify Surgical Procedures
- 1. Gecko Biomedical Confidential Maria Pereira April 2015 1
- 2. Gecko Biomedical Confidential Since 30.000 BC…. Tissue damage Technically challenging Leaks Ineffective in friable tissues Time consuming 2
- 3. Wound closure: a large and growing market $11.9 Billion in 2014 (7% CAGR) 160+ million of wounds closed per year 60+% are surgical wound related Adhesives and sealants represent 20% (≈$2.4B in 2014) 45% growth over 2010-2015 Gecko Biomedical Confidential3
- 4. Current sealants and adhesives suffer from poor design Non-synthetic or with high toxicity Lack of mechanical compatibility or good adhesion with tissue Reactive to body fluids Usage limited to open-surgery “an ideal surgical glue should meet three basic criteria. It should bond tissues strongly, it should be nontoxic and it should work in wet environments like those found inside the body. Unfortunately, “there isn’t really anything out there that can do all three of those, You can pick two, and that’s easy, but getting all three is really pretty tricky.” Jonathan Wilker, Purdue University in West Lafayette, Indiana Gecko Biomedical Confidential4
- 6. ExclusiveWW license form MIT on a portfolio of 6 patents 3 new patents filed by Gecko in 2015 A light activated adhesive to simplify surgical procedures GeneralsurgeryMIS Gecko Biomedical Confidential Cardiovascular: challenging unmet need Customizable mechanical profile Customizable biodegradation profile Cell ingrowth compatible Biocompatible Adhesion to different surgical materials Adhesion after body fluid exposure (viscous and hydrophobic) Fast on demand adhesion 6
- 7. Gecko Biomedical Confidential A light activated adhesive to simplify surgical procedures Sealant for tissue leaks A Adhesive patch for defect closure B Reduce the number of sutures: - Safer procedures - Faster procedures - Minimally invasive procedures - Less tissue damage Avoid the use of sutures: - Faster procedures - Minimally invasive procedures - Less tissue damage 7
- 8. Lang, N. et al (2014) “A Blood-Resistant Surgical Glue for Minimally Invasive Repair of Vessels and Heart Defects,” Sci. Transl. Med. 6, 218ra6 (2014) April 17th 2014 - N Engl J Med 2014; 370:1556-1559 Gecko Biomedical received “RadTech’s Emerging Technology Award” at RadTech 2014 A tool to transform how surgery is done: from open to minimally invasive procedures Gecko Biomedical Confidential8
- 9. Sealing vessel with reduced number of sutures Gecko Biomedical Confidential Adjunct to sutures: first clinical indication ( targeted for 2016) 9
- 10. Patching holes in infants hearts Gecko Biomedical Confidential Porcine animal model Multidisciplinary team 10
- 11. Gecko Biomedical Confidential • World Class team • Paradigm shift in Sealants, Adhesives and Minimally Invasive Surgery • Strong IP • Established ecosystem • Sustainable options for growth • Strong financial position with an €8M Series A and €4M non dilutive cash (2014-2016) 11